# A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection

Source: https://onco.cc/trials/nct05489289/  
OnCo record `nct05489289` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Cadonilimab in hepatocellular carcinoma, run by Akeso, now recruiting.

## Summary

A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection is a phase 3 interventional study registered as NCT05489289 by Akeso, with 570 participants planned, started 2023-01-05 and due to reach its primary completion in 2026-01-28. Interventions recorded: AK104, placebo. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05489289
- Phase: 3
- Setting: A Randomized, Double-blind, Phase III Clinical Study on the Efficacy and Safety of AK104 Versus Placebo as Adjuvant Therapy for Hepatocellular Carcinoma With High Risk of Recurrence After Curative Resection
- Sponsor: Akeso
- Enrolled: 570

## Sources

- ClinicalTrials.gov NCT05489289: https://clinicaltrials.gov/study/NCT05489289

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Cadonilimab](https://onco.cc/drugs/cadonilimab/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct05489289.json